Cited 39 times in
Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvant Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 김남규 | - |
dc.contributor.author | 김호근 | - |
dc.contributor.author | 민병소 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 최진섭 | - |
dc.date.accessioned | 2020-08-14T03:13:19Z | - |
dc.date.available | 2020-08-14T03:13:19Z | - |
dc.date.issued | 2007-12 | - |
dc.identifier.issn | 0378-584X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/178630 | - |
dc.description.abstract | Background: The efficacy and safety of a combination of cetuximab, irinotecan, and 5-fluorouracil/leucovorin (FOLFIRI) in downsizing unresectable colorectal liver metastases was investigated. Patients and methods: Patients with unresectable colorectal liver metastases with or without resectable extrahepatic metastasis were enrolled. 23 patients initially received 400 mg/m2 of cetuximab, followed by a weekly infusion of 250 mg/m2 and a biweekly dose of irinotecan (180 mg/m2), with 5-fluorouracil both by bolus (400 mg/m2) and by a 46-h infusion (total of 2,400 mg/m2) with leucovorin (400 mg/m2). Results: The overall response rate was 39.1% (n = 9; 95% confidence interval (CI): 17.6-60.7%). The most common grade 3-4 toxicities were skin reactions (30.4%) and diarrhea (26.1%). The rate of conversion to resectable liver metastases was 30.4% (n = 7; 95% CI: 10.1-50.8%). The factors found to be significantly associated with R0 resection were lower serum carcinoembryonic antigen levels after chemotherapy (p = 0.039), being chemonaive (p = 0.002), and showing a higher incidence of grade 3-4 skin toxicity (p = 0.011). Conclusions: Cetuximab with FOLFIRI may be an effective and safe treatment option for downsizing unresectable colorectal liver metastases. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | German, English | - |
dc.publisher | Karger | - |
dc.relation.isPartOf | ONKOLOGIE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adenocarcinoma / drug therapy* | - |
dc.subject.MESH | Adenocarcinoma / secondary* | - |
dc.subject.MESH | Adenocarcinoma / surgery | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Camptothecin / administration & dosage | - |
dc.subject.MESH | Camptothecin / adverse effects | - |
dc.subject.MESH | Camptothecin / analogs & derivatives | - |
dc.subject.MESH | Chemotherapy, Adjuvant / methods | - |
dc.subject.MESH | Colorectal Neoplasms / drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms / surgery | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil / administration & dosage | - |
dc.subject.MESH | Fluorouracil / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin / administration & dosage | - |
dc.subject.MESH | Leucovorin / adverse effects | - |
dc.subject.MESH | Liver Neoplasms / drug therapy* | - |
dc.subject.MESH | Liver Neoplasms / secondary* | - |
dc.subject.MESH | Liver Neoplasms / surgery | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvant Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Byung Soh Min | - |
dc.contributor.googleauthor | Nam Kyu Kim | - |
dc.contributor.googleauthor | Jung Bai Ahn | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Jin Sub Choi | - |
dc.contributor.googleauthor | Seung Hwan Cha | - |
dc.contributor.googleauthor | Hogeun Kim | - |
dc.identifier.doi | 10.1159/000109957 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A00353 | - |
dc.contributor.localId | A01183 | - |
dc.contributor.localId | A01402 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A04199 | - |
dc.relation.journalcode | J02423 | - |
dc.identifier.eissn | 1423-0240 | - |
dc.identifier.pmid | 18063876 | - |
dc.identifier.url | https://www.karger.com/Article/Abstract/109957 | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 김남규 | - |
dc.contributor.affiliatedAuthor | 김호근 | - |
dc.contributor.affiliatedAuthor | 민병소 | - |
dc.contributor.affiliatedAuthor | 안중배 | - |
dc.contributor.affiliatedAuthor | 최진섭 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 637 | - |
dc.citation.endPage | 643 | - |
dc.identifier.bibliographicCitation | ONKOLOGIE, Vol.30(12) : 637-643, 2007-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.